Market Place
Sourcing Support
Exclusive: US FDA finds new manufacturing lapses at Eli Lilly plant
20 Jan 2024 //
REUTERS
Teva drops migraine-drug patent case against Eli Lilly
25 Nov 2023 //
REUTERS
Eli Lilly`s migraine drug fails to prove superiority to Pfizer`s
17 Jun 2023 //
REUTERS
First-Of-Its-Kind Head-to-Head Clinical Trial Reaffirms the Efficacy of Emgality
16 Jun 2023 //
PR NEWSWIRE
AffaMed Therapeutics to commercialize Galcanezumab for Migraine Prevention
17 Jan 2023 //
PR NEWSWIRE
Eli Lilly hit by migraine drug launch slowdown, but rivals jump
06 Aug 2022 //
FIERCEPHARMA
Lilly begins enrolment in Phase IV trial of Emgality for migraine prevention
22 Nov 2021 //
CLINICALTRIALSARENA
Eli Lilly, Daiichi Sankyo partner to commercialize lasmiditan succinate in Japan
31 Aug 2021 //
PHARMABIZ
AbbVie`s oral migraine treatment atogepant nears FDA decision
20 Aug 2021 //
FIERCEBIOTECH
Emgality (galcanezumab) now approved for use in Canada for episodic cluster
25 Feb 2021 //
BIOSPACE
Sanofi works with Parkinson`s Foundation on genetic testing
19 Nov 2020 //
FIERCE PHARMA
NICE recommends Lilly`s Emgality for chronic and episodic migraine
18 Nov 2020 //
PHARMAFILE
Eli Lilly collaborates with Daiichi Sankyo for commercialisation migraine drug
02 Nov 2020 //
BIOSPECTRUMASIA
Eli Lilly and Daiichi Sankyo Enter Commercialization Collaboration in Japan
30 Oct 2020 //
PRESS RELEASE
Migraine drug galcanezumab offers hope for millions of sufferers
16 Oct 2020 //
THETIMES
Lilly touts Emgality`s ability to reduce patients` overall pain
18 Jun 2020 //
FIERCE PHARMA
Emgality® Demonstrates Reduction in Frequency, Duration, and Pain Severity
17 Jun 2020 //
PR NEWSWIRE
Phase 3 CONQUER study shows Emgality improves work productivity and health
26 May 2020 //
PHARMABIZ
Lilly, mid-Emgality launch, cues real-world study migraine study
19 Dec 2019 //
FIERCE PHARMA
Racing after the leaders, Eli Lilly`s migraine drug clears another pivotal study
06 Aug 2019 //
ENDPTS
Post-Hoc Analyses of Phase 3 Pivotal Studies of Emgality® Show Improvements
11 Jul 2019 //
PR NEWSWIRE
Lilly Bio-Medicines chief Christi Shaw steps aside, leaving key launches behind
11 Jul 2019 //
FIERCE PHARMA
Biohaven, sporting new data, moves closer to CGRP finish line—and maybe M&A
11 Jul 2019 //
FIERCE PHARMA
Studies explore treatments to prevent cluster headaches, quell migraines
10 Jul 2019 //
REUTERS
Lilly enlists patients to raise cluster headache awareness
26 Jun 2019 //
FIERCE PHARMA
Lilly`s scored its cluster headache nod for Emgality
05 Jun 2019 //
FIERCE PHARMA
Lilly`s new migraine drug pulls ahead of Amgen in fierce battle for new prescriptions
12 May 2019 //
REUTERS
Eli Lilly`s Emgality shows positive Phase 3 results in treatment of migraine
08 May 2019 //
PHARMAFILE
Eli Lilly ph3 studies of Emgality shows reduction in monthly migraine headache
06 May 2019 //
PHARMABIZ
Lilly Receives FDA Priority Review Designation for Emgality® Injection
05 Mar 2019 //
BIOSPACE
Can Botox hang with CGRP in migraine? Allergan says yes
15 Jan 2019 //
FIERCE PHARMA
Lilly (LLY) to Acquire Pain Candidate From Private Biotech
22 Dec 2018 //
YAHOO NEWS
Eli Lilly next big bet on next-gen pain drug, buying Hydra assets
17 Dec 2018 //
ENDPTS
Top 9 Really Cool Life Science Discoveries of the Year
10 Dec 2018 //
BIOSPACE
Eli Lilly weighs $200M-plus sale of declining China drug portfolio: report
17 Nov 2018 //
FIERCE PHARMA
Lilly Submits NDA to FDA for Lasmiditan, Receives BTH Designation for EmgalitY
15 Nov 2018 //
PR NEWSWIRE
Eli Lilly files for FDA approval of migraine drug lasmiditan
15 Nov 2018 //
FIERCE BIOTECH
Amgen, Lilly migraine drugs make it onto Express Scripts` preferred list
17 Oct 2018 //
BIOPHARMA DIVE
Teva has buyer for plant in Israel that could save 200 jobs: report
10 Oct 2018 //
FIERCE PHARMA
Was last week`s Teva sell-off warranted? Depends who you ask
03 Oct 2018 //
FIERCE PHARMA
Ajovy (fremanezumab) : Teva Pharmaceuticals vs. Eli Lilly
02 Oct 2018 //
PATENT LITIGATION
Eli Lilly Migraine Drug Approved, the Third in New Class of Medicines
28 Sep 2018 //
XCONOMY
Three new drugs will compete fiercely to revolutionize migraine treatment
28 Sep 2018 //
MARKET WATCH
Eli Lilly says FDA has approved new migraine drug Emgality
27 Sep 2018 //
MARKET WATCH
FDA Approved Eli Lilly`s Emgality
27 Sep 2018 //
BUSINESS INSIDER
CHMP puts 13 therapies forward for EU approval
24 Sep 2018 //
PHARMA TIMES
New medicine for the prevention of migraine
22 Sep 2018 //
EMA
Lilly Receives +ve CHMP Opinion for galcanezumab in Migraine Prophylaxis
21 Sep 2018 //
PR NEWSWIRE
Aimovig`s launch trends `bode well` for other CGRPs: analyst
21 Aug 2018 //
FIERCE PHARMA
